

**Freedom of Information Act 2000 - Request Reference Fol/21/319**  
**Biologic Medication for Rheumatology and Dermatology**

**Request Details**

I am analysing the usage of new biologic medications for the treatment of dermatological and rheumatologic conditions. I would greatly appreciate if you could answer the following two questions.

1. How many patients were treated in June 2021 (or latest available month) by the dermatology department with the following drugs:

Baricitinib (Olumiant)	0
Dupilumab (Dupixent)	54
Ixekizumab (Taltz)	17
Risankizumab (Skyrizi)	14
Guselkumab (Tremfya)	10
Secukinumab (Cosentyx)	35

2. How many patients were treated in June 2021 (or latest available month) by the rheumatology department with the following drugs:

Baricitinib (Olumiant)	39
Filgotinib (Jyseleca)	0
Ixekizumab (Taltz)	5
Secukinumab (Cosentyx)	28
Upadacitinib (Rinvoq)	*

Please note that Section 40 of the Freedom of Information Act 2000 has been applied where information in the above table has been replaced with an asterisk. The UHB will not provide these exact numbers due to the low numbers of individuals involved (5 or less). The UHB believes there is a potential risk of individuals being able to be identified, when considered with other information already available within the public domain, if this was disclosed. Therefore, the data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.